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Reimplanting Previously Infected Device in the Same
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From the Cardiovascular Center, University of Michigan Health System, Ann Arbor, Michigan
Since the introduction of pacing, and sub-
sequently defibrillation, cardiac rhythm man-
agement devices (CRMDs) have brought the
improvement in quality of life as well as extended
longevity of patients with sick sinus syndrome,
complete heart block, and life-threatening ventric-
ular arrhythmias. Unfortunately, despite decades
of widespread use, the benefits of CRMDs do not
reach all patients who need them. There remains
a great disparity in access to this essential therapy
between patients in the advanced economies
and low- and middle-income countries, largely
due to high cost.1 In order to improve access
to pacemakers and defibrillators in underserved
nations, organizations such as My Heart Your
Heart, Pace4Life, and many others have partnered
with the funeral and crematory industry to harvest
CRDMs postmortem for their potential reuse.2
Funeral home director surveys and patient/general
population surveys indicate support for this
concept.3
Over the years, many single center and
mostly uncontrolled and retrospective studies
have suggested that pacemaker reuse may be
safe and effective, offering patients a therapeutic
option they are otherwise denied due to lack of
insurance and/or resources.4 Recent publications
have added to the body of evidence that CRMDs
may be safely reimplanted. Kantharia et al.5
have reported on a retrospective cohort of 53
patients who received postmortem refurbished
pacemakers in Mumbai, India. No infections or
device-related failures occurred over mean follow-
up of 21 months. Ninety-five percent of patients
reported marked improvement in their symptoms.
In another report, Pavri et al.6 described a
consecutive series of 81 patients who underwent
implantation of 106 implantable cardioverter de-
fibrillators obtained either postmortem or during
device upgrades. No infectious complications
occurred during a mean follow-up of 825 days,
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and there was no malfunction related to the
reused device. Appropriate therapy (shocks or
antitachycardia pacing) was delivered in 54.3%
patients, undoubtedly saving many lives. Neither
of the two studies had a control arm.
Nava et al.7 added to our knowledge of
CRMD reuse when they presented data on
603 consecutive patients in an ambispective
noninferiority study. The study group patients
(n = 307) received resterilized pacemakers,
96% of them from cadaveric donation, and the
control group patients (n = 296) received a
new pacemaker. A combined end point of three
major outcomes—unexpected battery depletion,
infection, and device malfunction—was reached
in 5.5% in the control group and 7.2% in the
study group (P = 0.794). Five new pacemakers
(1.7%) and 11 resterilized pacemakers (3.6%) had
unexpected battery depletion (P = 0.116); 3.7%
new pacemakers and 3.2% reused pacemakers had
a procedure-related infection (P = 0.466); and one
pacemaker in the study group malfunctioned. The
authors concluded that other than the expected
shorter battery life, reuse of pacemaker generators
was not inferior to the use of new devices.
In this issue of Pacing and Clinical Electro-
physiology, Feng and colleagues report on 212
patients who were treated for CRMD infection at
the Peking University People’s Hospital, Beijing,
China.8 All patients underwent a removal of
their CRMD. One hundred thirteen patients could
afford and underwent reimplantation of a brand
new CRMD (control group). Ninety-nine patients
underwent reimplantation of the infected device
after cleaning and resterilization (study group).
Following extraction, CRMDs were placed in a
solution of 70% ethanol for 30 minutes, then
washed with pipe cleaners and other instruments
to make sure that all debris was removed from
the orifices of the devices. CRMDs had to have
at least 4 years of expected longevity remaining.
CRMDs were packed and sterilized with 24-hour
ethylene oxide gas. All patients in the study group
underwent reimplantation of the same pacemaker
generator.
The primary end point in the study was
a composite of infection, unexpected battery
depletion, or devicemalfunction, andwas reached
in 10 patients—five in the study group and
©2014 Wiley Periodicals, Inc.
938 August 2014 PACE, Vol. 37
REIMPLANTING PREVIOUSLY INFECTED DEVICE IN THE SAME PATIENT
five in the control group. Recurrent infection
occurred in three patients in the study group
and two patients in the control group (3.0%
vs 1.7%; relative risk, 0.96; 95% confidence
interval, 0.35–2.03; P = 0.561). There was no
premature battery depletion in either group. Five
patients experienced device malfunction—high
pacing threshold and/or failure to sense—two of
who were in the study group and three in the
control group. As in the prior studies, brand new
leads were implanted with refurbished devices.
The cost of the lead(s) usually represents less than
10–15% of the cost of the device, and either the
families or charities have provided the necessary
funds to cover this expense.
This study is a valuable addition to the
growing body of evidence supporting CRMD reuse.
It offers a pragmatic approach for patients with
limited resources who develop CRMD infection.
Device extraction is necessary in order to erad-
icate device-related bacteremia or device pocket
infection.9 Patients with already limited resources
face a double challenge if their device becomes in-
fected during the immediate postoperative period.
The study also opens the door to the possibility
of harvesting infected CRMDs in the high-income
countries in order to offer them to patients in low-
and middle-income countries, after appropriate
cleaning and resterilization. While the study
was not randomized—the assignment into the
treatment group was made based on the patient’s
ability to fund a new implant—it shows that reim-
plantation of CRMD is safe and effective. Further
studies are needed before the practice of pace-
maker reuse can be embraced. A prospective mul-
ticenter trial, based on a validated sterilization and
electrical testing protocol, is needed to provide the
definitive data on safety and efficacy. Should such
study succeed, it will be impossible to ignore its
results, and innumerable lives will be saved.
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